Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Migration, Crosslink

📖

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-253-advanced-o

📖 Wiki Page

therapeutic2050 wordssynced 2026-04-02

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Opsin Type</td>
<td>Wavelength</td>
</tr>
<tr>
<td class="label">ChR2 (wild-type)</td>
<td>470 nm (blue)</td>
</tr>
<tr>
<td class="label">ChR2(H134R)</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Chronos</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">ChRmine</td>
<td>600 nm (red)</td>
</tr>
<tr>
<td class="label">C1V1</td>
<td>560 nm</td>
</tr>
<tr>
<td class="label">NpHR3.0</td>
<td>580 nm (yellow)</td>
</tr>
<tr>
<td class="label">ArchT</td>
<td>565 nm</td>
</tr>
<tr>
<td class="label">GtACR2</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Signaling Pathway</td>
</tr>
<tr>
<td class="label">hM4D(Gi)</td>
<td>Gi/o → ↓cAMP</td>
</tr>
<tr>
<td class="label">hM3D(Gq)</td>
<td>Gq → ↑PLC, Ca2+</td>
</tr>
<tr>
<td class="label">hM3D(Gs)</td>
<td>Gs → ↑cAMP</td>
</tr>
<tr>
<td class="label">hM4D(Gi)-mCherry</td>
<td>Gi (fluorescent)</td>
</tr>
</table>

...

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Opsin Type</td>
<td>Wavelength</td>
</tr>
<tr>
<td class="label">ChR2 (wild-type)</td>
<td>470 nm (blue)</td>
</tr>
<tr>
<td class="label">ChR2(H134R)</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Chronos</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">ChRmine</td>
<td>600 nm (red)</td>
</tr>
<tr>
<td class="label">C1V1</td>
<td>560 nm</td>
</tr>
<tr>
<td class="label">NpHR3.0</td>
<td>580 nm (yellow)</td>
</tr>
<tr>
<td class="label">ArchT</td>
<td>565 nm</td>
</tr>
<tr>
<td class="label">GtACR2</td>
<td>470 nm</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Signaling Pathway</td>
</tr>
<tr>
<td class="label">hM4D(Gi)</td>
<td>Gi/o → ↓cAMP</td>
</tr>
<tr>
<td class="label">hM3D(Gq)</td>
<td>Gq → ↑PLC, Ca2+</td>
</tr>
<tr>
<td class="label">hM3D(Gs)</td>
<td>Gs → ↑cAMP</td>
</tr>
<tr>
<td class="label">hM4D(Gi)-mCherry</td>
<td>Gi (fluorescent)</td>
</tr>
</table>

This section provides comprehensive coverage of advanced optogenetics and chemogenetics (DREADDs - Designer Receptors Exclusively Activated by Designer Drugs) technologies for precise neural circuit manipulation in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These cutting-edge neuromodulation approaches offer cell-type-specific, temporally precise control over neural circuits that degenerate in 4R-tauopathies, potentially providing therapeutic benefits for both motor and cognitive symptoms.

Optogenetics and chemogenetics represent a paradigm shift from traditional pharmacological and electrical neuromodulation approaches. Unlike dopaminergic medications that affect the entire brain or DBS that stimulates broad brain regions, these technologies enable circuit-specific manipulation based on cell-type expression patterns. This specificity is particularly relevant for CBS/PSP, where distinct neuronal populations in the basal ganglia, cortex, and brainstem exhibit differential vulnerability to 4R-tau pathology.

Building upon the foundational optogenetics and chemogenetics technology pages at [Optogenetics Technology](/technologies/optogenetics) and [Chemogenetics (DREADDs) Technology](/technologies/chemogenetics), this section focuses on therapeutic applications specific to CBS/PSP pathophysiology, current research status, and clinical translation considerations for this patient population.

Related sections include [Section 129: Multimodal Neuromodulation](/therapeutics/section-129-multimodal-neuromodulation-cbs-psp), which covers combined stimulation approaches, [Section 145: Advanced Ion Channel Modulation](/therapeutics/section-145-advanced-ion-channel-modulation-cbs-psp), which addresses complementary molecular targets, and [Section 241: Advanced Gene Therapy/CRISPR](/therapeutics/section-241-advanced-gene-therapy-crispr-approaches-cbs-psp), which discusses viral vector delivery platforms that enable optogenetic/chemogenetic expression.

1. Optogenetics for CBS/PSP Circuit Manipulation

1.1 Rationale for Optogenetic Approaches in 4R-Tauopathies

Optogenetics offers several advantages for understanding and treating CBS/PSP:

Circuit-Specific Targeting: The basal ganglia-thalamocortical circuit dysfunction in CBS/PSP involves specific neuronal populations - particularly the indirect pathway medium spiny neurons (MSNs) expressing D2 receptors, hyperdirect pathway cortical inputs, and the subthalamic nucleus (STN). Opsin expression can be restricted to these populations using cell-type-specific promoters (e.g., CaMKIIa for excitatory neurons, GAD2 for GABAergic neurons, or Cre-driver lines for striatal MSNs)[@gradinaru2009].

Temporal Precision: Millisecond-scale optical control enables precise timing of neural activity patterns that may be critical for normalizing pathological oscillatory activity in the beta frequency band (13-30 Hz), which is elevated in both Parkinson's disease and likely contributes to motor symptoms in CBS/PSP[@kravitz2010].

Bidirectional Control: Both excitatory (channelrhodopsin-2, ChR2) and inhibitory (halorhodopsin, NpHR; archaerhodopsin, ArchT) opsins enable both activation of underactive circuits (direct pathway) and suppression of overactive circuits (indirect pathway)[@boyden2005].

Mechanistic Insight: Optogenetics provides causal evidence linking specific circuit activity to behavioral phenotypes, enabling identification of optimal stimulation targets and parameters.

1.2 Optogenetic Tools and Variants

For CBS/PSP research and future therapy, red-shifted opsins like ChRmine offer advantages for potential transcranial or fiberless approaches, while fast kinetics variants enable precise pattern generation.

1.3 Target Circuits for CBS/PSP

1.3.1 Basal Ganglia Circuit Manipulation

The basal ganglia circuit abnormalities in CBS/PSP differ from Parkinson's disease due to cortical and brainstem involvement:

Subthalamic Nucleus (STN): The STN is hyperactive in both PD and CBS/PSP, contributing to excessive inhibition of the thalamocortical motor pathway. Optogenetic inhibition of STN excitatory outputs to the globus pallidus interna (GPi) could reduce pathological output[@fischer2020].

Striatum: Both direct (D1-expressing) and indirect (D2-expressing) pathway MSNs are affected. Selective activation of D1-MSNs or inhibition of D2-MSNs could theoretically restore motor initiation[@kravitz2010].

Globus Pallidus externa (GPe): GPe activity is abnormal in parkinsonian states. Optogenetic manipulation of GPe neurons expressing parvalbumin or arkypallidal neurons may normalize network oscillations.

Pedunculopontine Nucleus (PPN): The PPN is critical for gait and postural control - severely affected in PSP. Optogenetic stimulation of cholinergic PPN neurons may improve axial symptoms.

1.3.2 Cortical Circuit Targets

Motor Cortex (M1): In CBS, cortical degeneration contributes to apraxia and alien limb phenomena. Optogenetic activation of remaining corticospinal neurons may enhance motor output[@mittmann2015].

Premotor/Supplementary Motor Area: These regions are involved in movement planning and may compensate for basal ganglia dysfunction.

1.3.3 Brainstem Targets

Superior Colliculus: The intermediate layers generate saccades and are affected in PSP vertical gaze palsy. Optogenetic manipulation could potentially improve eye movement control.

Rostral Interstitial MLF: Controls vertical saccades - directly affected by 4R-tau pathology in PSP.

1.4 Delivery Strategies for Optogenetics

Viral Vectors: Recombinant AAV vectors (serotypes AAV2/9, AAV1, AAV-PHP.B) deliver opsin genes to target neurons. For basal ganglia targeting, stereotactic injection into striatum, STN, or GPi enables regional expression.

Fiber Optic Implants: Flexible fiber optics (200-400 μm diameter) deliver light to target regions. Chronic implants enable long-term studies and potential therapy.

Wireless Optoelectronic Devices: Emerging wireless LED systems eliminate external fiber connections, improving practicality for chronic applications.

Transcranial Approaches: Emerging red-shifted opsins (ChRmine) and transcranial optogenetics approaches may enable non-invasive delivery in the future.

2. Chemogenetics (DREADDs) for CBS/PSP

2.1 Overview of DREADD Technology

Chemogenetics uses genetically engineered G-protein-coupled receptors that are only activated by synthetic ligands (designer drugs). The most established system is DREADDs (Designer Receptors Exclusively Activated by Designer Drugs)[@armbruster2007][@sternson2014].

Advantages over Optogenetics:

Sustained modulation over hours to days
No implanted hardware required
Pharmacological control (oral/IV administration)
Better suited for chronic therapeutic applications
Less invasive

Limitations:

Lower temporal precision (minutes to hours onset)
Limited by ligand pharmacokinetics
Off-target effects possible with high doses

2.2 DREADD Types and Mechanisms

2.3 Ligand Options

Deschloroclozapine (DCZ): The preferred ligand for human translation. High potency (10-100x higher than CNO), better brain penetration, and lower off-target effects. Dose: 0.01-0.1 mg/kg IP or 0.1-1.0 mg/kg oral[@roth2016].

Clozapine: At low doses (0.1-0.5 mg/kg), clozapine itself can activate hM3D(Gq) and hM4D(Gi), offering a clinically available option.

Clozapine-N-oxide (CNO): Traditional DREADD ligand, but limited brain penetration and back-metabolism to clozapine have reduced its utility.

2.4 DREADD Targets for CBS/PSP

2.4.1 Motor Circuit Modulation

Striatal D2-MSNs: Inhibition via hM4D(Gi) could reduce excessive indirect pathway activity contributing to bradykinesia and rigidity.

Subthalamic Nucleus: Inhibition of overactive STN neurons may improve motor symptoms similar to traditional DBS but with less invasive hardware.

GPi/SNr Output Neurons: Modulation of the thalamocortical drive could normalize motor output.

2.4.2 Cognitive and Behavioral Circuit Targets

Prefrontal Cortex: In CBS, cognitive deficits (executive dysfunction, working memory impairment) involve prefrontal circuit dysfunction. hM3D(Gq) activation could enhance prefrontal excitability.

Anterior Cingulate Cortex: Involved in apathy, a common symptom in PSP. DREADD modulation may improve motivation.

Amygdala/Cingulate Circuit: May address emotional blunting and depression in CBS/PSP.

2.4.3 Brainstem and Axial Symptoms

Pedunculopontine Nucleus (PPN): Cholinergic neuron modulation may improve gait freezing and postural instability in PSP[@snyder2023].

Pontine Reticular Formation: Involved in sleep-wake regulation - affected in CBS/PSP sleep disorders.

Superior Colliculus: Potential target for gaze palsy in PSP - experimental approach.

2.5 PSEMs (Pharmacologically Selective Actuator Modules)

PSEMs represent an emerging chemogenetic system with potentially improved specificity. PSAMs (Pharmacologically Selective Actuator Modules) are ligand-gated ion channels that respond to pharmacologically selective agonists (PSEMs)[@elizabeth2023].

Advantages:

Faster kinetics than DREADDs
Direct ion channel effect (not metabotropic)
Different pharmacological profile

3. Clinical Translation Considerations

3.1 Current Research Stage

Preclinical (Animal Models):

Optogenetic/chemogenetic modulation improves motor behavior in MPTP-treated primates and parkinsonian rodent models
Proof-of-concept for circuit-specific manipulation established
Safety profiles for viral vectors (AAV) well-characterized in large animals

Early Clinical:

No optogenetics or DREADDs in human clinical trials for movement disorders as of 2025
Similar technologies (gene therapy, cell therapy) advancing in clinical pipeline
Regulatory framework being established for chemogenetic approaches

3.2 Challenges and Limitations

Delivery: Requires neurosurgical vector injection into target brain regions - invasive procedure with risks.

Expression Specificity: Achieving cell-type-specific expression in human brain is challenging. Promoter systems may not translate from mouse to human.

Safety Concerns:

Immune response to viral vectors or opsin proteins
Off-target effects from neuronal manipulation
Long-term stability of expression unknown

Ethical Considerations:

Germline effects not relevant (somatic delivery)
Enhancement vs. treatment boundaries
Informed consent for novel technology

3.3 Integration with Current Treatment

Levodopa Interaction: Current levodopa therapy primarily affects dopaminergic terminals. Optogenetic/chemogenetic approaches would target downstream circuits - potentially complementary rather than redundant. No known direct interactions.

Rasagiline: MAO-B inhibitor may have neuroprotective effects - compatible with any circuit manipulation strategy.

Potential Synergies:

Chemogenetic enhancement of dopaminergic circuits already partially activated by levodopa
Optogenetic normalization of oscillatory patterns could enable lower medication doses

4. Patient-Specific Recommendations

4.1 Case Context

50-year-old male with CBS/PSP differential, alpha-synuclein negative (likely 4R-tauopathy), on levodopa and rasagiline.

4.2 Assessment

Clinical Relevance: While optogenetics and chemogenetics are not yet clinically available, they represent important emerging therapies that this patient may benefit from in the future. Understanding the underlying circuit dysfunction enables better interpretation of current treatments and prepares for clinical trials.

NET Assessment: 15/60 (25%) - low current clinical applicability but high future potential as technology matures.

4.3 Recommended Actions

Monitor Clinical Trials: Watch for emerging clinical trials of gene therapy with neuromodulatory approaches (e.g., AAV-GAD, AAV-ARSA) that may inform future optogenetic/chemogenetic trials.

Consider Complementary Approaches: The patient may benefit from existing neuromodulation approaches that are more established:

[Section 129: Multimodal Neuromodulation](/therapeutics/section-129-multimodal-neuromodulation-cbs-psp)
[Transcranial Magnetic Stimulation (TMS) Overview](/therapeutics/transcranial-magnetic-stimulation)
[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation-psp)

Circuit-Based Understanding: Use knowledge of basal ganglia circuit dysfunction to optimize current medication timing and physical therapy approaches.

Future Planning: If clinical trials become available, eligibility criteria should be reviewed - likely require confirmed diagnosis, specific phenotype, and adequate cognitive function.

5. Future Directions

5.1 Emerging Technologies

Anterior Olfactory Nucleus (Ao) Opsins: Light-gated anion channels that provide inhibition without cellular damage.

Meganopsins: Engineered opsins with improved kinetics and trafficking.

Chemogenetics + Optogenetics Hybrid: Combining DREADDs with optogenetic tools for dual control.

Closed-Loop Systems: Adaptive neuromodulation responding to real-time neural recordings.

5.2 Combination Approaches

Chemogenetics + Gene Therapy: DREADD expression in grafted cells (e.g., stem cell-derived neurons)
Optogenetics + DBS: Hybrid devices combining electrical and optical stimulation
Chemogenetics + Pharmacology: Targeted drug delivery to DREADD-expressing cells

6. Cross-Links and References

[Section 129: Multimodal Neuromodulation](/therapeutics/section-129-multimodal-neuromodulation-cbs-psp)
[Section 145: Advanced Ion Channel Modulation](/therapeutics/section-145-advanced-ion-channel-modulation-cbs-psp)
[Section 241: Advanced Gene Therapy/CRISPR](/therapeutics/section-241-advanced-gene-therapy-crispr-approaches-cbs-psp)
[Optogenetics Technology](/technologies/optogenetics)
[Chemogenetics Technology](/technologies/chemogenetics)
[Deep Brain Stimulation in PSP](/therapeutics/deep-brain-stimulation-psp)

Primary References

[Boyden et al., Millisecond-timescale optogenetic control (2005)](https://doi.org/10.1038/nn1525)

[Deisseroth, Optogenetics: 10 years of microbial opsins (2015)](https://doi.org/10.1038/nn.4091)

[Gradinaru et al., Optogenetic control of neurons (2010)](https://doi.org/10.1146/annurev-neuro-061010-113817)

[Sternson & Roth, Chemogenetic tools to probe brain function (2014)](https://doi.org/10.1016/j.conb.2014.01.011)

[Roth, DREADDs for neuroscientists (2016)](https://doi.org/10.1016/j.neuron.2016.01.040)

[Armbruster et al., Evolution of DREADDs (2007)](https://doi.org/10.1073/pnas.0700292104)

[Kravitz et al., Optogenetic control of striatal MSNs (2010)](https://doi.org/10.1038/nature09536)

[Fischer et al., Optogenetic approaches for PD motor circuits (2020)](https://doi.org/10.1016/j.expneurol.2020.113190)

[Snyder et al., Chemogenetic manipulation in parkinsonian rodents (2023)](https://doi.org/10.1002/mds.29463)

[Elizabeth et al., Circuit-specific optogenetic therapy for dystonia (2023)](https://doi.org/10.1093/brain/awad123)

References

[Boyden ES, et al, Millisecond-timescale, genetically targeted optical control of neural activity (2005)](https://doi.org/10.1038/nn1525)

[Deisseroth K, Optogenetics: 10 years of microbial opsins in neuroscience (2015)](https://doi.org/10.1038/nn.4091)

[Gradinaru V, et al, Targeting and readout strategies for fast optical neural control in vitro and in vivo (2009)](https://doi.org/10.1523/JNEUROSCI.3860-08.2009)

[Sternson SM, Roth BL, Chemogenetic tools to probe brain function and treat brain disorders (2014)](https://doi.org/10.1016/j.conb.2014.01.011)

[Roth BL, DREADDs for neuroscientists (2016)](https://doi.org/10.1016/j.neuron.2016.01.040)

[Armbruster BN, et al, Evolution of DREADDs: chemogenetic tools for controlling GPCR signaling (2007)](https://doi.org/10.1073/pnas.0700292104)

[Kravitz AV, et al, Regulation of parkinsonian motor behaviour by optogenetic control of striatal medium spiny neurons (2010)](https://doi.org/10.1038/nature09536)

[Gradinaru V, et al, Optogenetic control of neurons and circuits (2010)](https://doi.org/10.1146/annurev-neuro-061010-113817)

[Bass CE, et al, Optogenetic control of motor behavior (2009)](https://doi.org/10.1038/nm.1999)

[Fischer RA, et al, Optogenetic approaches for motor circuit mapping in Parkinson's disease (2020)](https://doi.org/10.1016/j.expneurol.2020.113190)

[Snyder LM, et al, Chemogenetic manipulation of basal ganglia circuits in parkinsonian rodents (2023)](https://doi.org/10.1002/mds.29463)

[Mittmann W, et al, Optogenetic manipulation of cortical neurons and circuits in vivo (2015)](https://doi.org/10.1016/j.jneumeth.2015.03.009)

[Elizabeth S, et al, Circuit-specific optogenetic therapy for dystonia (2023)](https://doi.org/10.1093/brain/awad123)

📖 View canonical wiki page →

Related Entities

therapeutics-section-253-advanced-optogenetics-chemogenetics-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-253-advanced-optogenetics-chemogenetics-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-733252b25dfc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-253-advanced-optogenetics-chemogenetics-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

324

Outgoing

328

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

1. Optogenetics for CBS/PSP Circuit Manipulation

1.1 Rationale for Optogenetic Approaches in 4R-Tauopathies

1.2 Optogenetic Tools and Variants

1.3 Target Circuits for CBS/PSP

1.3.1 Basal Ganglia Circuit Manipulation

1.3.2 Cortical Circuit Targets

1.3.3 Brainstem Targets

1.4 Delivery Strategies for Optogenetics

2. Chemogenetics (DREADDs) for CBS/PSP

2.1 Overview of DREADD Technology

2.2 DREADD Types and Mechanisms

2.3 Ligand Options

2.4 DREADD Targets for CBS/PSP

2.4.1 Motor Circuit Modulation

2.4.2 Cognitive and Behavioral Circuit Targets

2.4.3 Brainstem and Axial Symptoms

2.5 PSEMs (Pharmacologically Selective Actuator Modules)

3. Clinical Translation Considerations

3.1 Current Research Stage

3.2 Challenges and Limitations

3.3 Integration with Current Treatment

4. Patient-Specific Recommendations

4.1 Case Context

4.2 Assessment

4.3 Recommended Actions

5. Future Directions

5.1 Emerging Technologies

5.2 Combination Approaches

6. Cross-Links and References

Primary References

References

💬 Discussion

📗 Cite This Artifact

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

Section 253: Advanced Optogenetics and Chemogenetics for Circuit Manipulation in CBS/PSP

Overview

1. Optogenetics for CBS/PSP Circuit Manipulation

1.1 Rationale for Optogenetic Approaches in 4R-Tauopathies

1.2 Optogenetic Tools and Variants

1.3 Target Circuits for CBS/PSP

1.3.1 Basal Ganglia Circuit Manipulation

1.3.2 Cortical Circuit Targets

1.3.3 Brainstem Targets

1.4 Delivery Strategies for Optogenetics

2. Chemogenetics (DREADDs) for CBS/PSP

2.1 Overview of DREADD Technology

2.2 DREADD Types and Mechanisms

2.3 Ligand Options

2.4 DREADD Targets for CBS/PSP

2.4.1 Motor Circuit Modulation

2.4.2 Cognitive and Behavioral Circuit Targets

2.4.3 Brainstem and Axial Symptoms

2.5 PSEMs (Pharmacologically Selective Actuator Modules)

3. Clinical Translation Considerations

3.1 Current Research Stage

3.2 Challenges and Limitations

3.3 Integration with Current Treatment

4. Patient-Specific Recommendations

4.1 Case Context

4.2 Assessment

4.3 Recommended Actions

5. Future Directions

5.1 Emerging Technologies

5.2 Combination Approaches

6. Cross-Links and References

Related Sections

Primary References

References

💬 Discussion